Baird Maintains Outperform on Regenxbio, Raises Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney has maintained an Outperform rating on Regenxbio (NASDAQ:RGNX) and increased the price target from $34 to $39.
March 06, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney reaffirmed an Outperform rating on Regenxbio and raised the price target from $34 to $39.
The increase in price target by Baird reflects a positive outlook on Regenxbio's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100